Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Months

Thaci, DiamantOhtsuki, MamitaroMaul, Julia-TatjanaSzegedi, AndreaLuna, Paula C.Lynde, Charles W.Soliman, Ahmed M.Wang, HongweiKaufmann, ChristianAshley, Doug G.Madihlaba, TshepisoRubant, SimonePapp, Kim A.2026-02-172026-02-172025Dermatology and Therapy. -15 : 2 (2025), p. 381-394. -Dermatol Ther (Heidelb). - 2193-8210. - 2190-91722193-82102190-9172https://hdl.handle.net/2437/404720Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25 Monthsfolyóiratcikkopen access articlehttps://ebib.lib.unideb.hu/ebib/CorvinaWeb?action=cclfind&resultview=long&ccltext=idno+BIBFORM135566OrvostudományokKlinikai orvostudományokhttps://link.springer.com/10.1007/s13555-025-01342-0szerzőhttp://dx.doi.org/10.1007/s13555-025-01342-02026-02-1700141403990000185217717458